Cardiff Oncology, Inc. - Common Stock (CRDF)

CRDF stock results show that Cardiff Oncology missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Finding good investing possibilities in the constantly changing stock market might be likened to unearthing buried jewels.

CRDF stock results show that Cardiff Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.

Cardiff Oncology's CRDF-004 trial shows promising onvansertib results in RAS-mutated mCRC patients, with higher tumor response rates and a strong safety profile.

These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around.

For speculators that don’t mind the rumblings of market volatility, these stocks under $5 could be quite attractive.

U.S. stocks traded lower toward the end of trading, with the S&P 500 edging lower on Monday. The Dow traded down 0.20% to 39,007.30 while the NASDAQ fell 0.18% to 16,245.77. The S&P 500 also fell, dropping, 0.01% to 5,137.05.

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its SEAL01 Bitcoin mining chip and amid overall strength in the price of Bitcoin.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Friday. The Dow traded up 0.23% to 39,084.47 while the NASDAQ rose 1.22% to 16,287.91. The S&P 500 also rose, gaining, 0.78% to 5,135.86.

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Friday. The Dow traded up 0.02% to 39,005.87 while the NASDAQ rose 0.63% to 16,193.95. The S&P 500 also rose, gaining, 0.40% to 5,116.75.

Cardiff Oncology's clinical update on ONSEMBLE trial data for onvansertib in second-line RAS-mutated metastatic colorectal cancer. Discover efficacy findings and the company's strategic shift towards first-line RAS-mutated mCRC.

Shares of NetApp, Inc. (NASDAQ: NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance.

Pre-market stock movers are worth checking on Friday as investors prepare for the last day of trading this week with all of the latest news!